LENZ THERAPEUTICS, INC. Noncash Merger Related Costs
LENZ THERAPEUTICS, INC. (LENZ) reported Noncash Merger Related Costs of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2025-07-30
- LENZ THERAPEUTICS, INC. noncash merger related costs for the quarter ending 2025-06-30 was $0.00.
- LENZ THERAPEUTICS, INC. noncash merger related costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. noncash merger related costs for the quarter ending 2024-06-30 was -$4.77M.
- LENZ THERAPEUTICS, INC. noncash merger related costs for the quarter ending 2024-03-31 was $4.82M.
| Period end | Noncash Merger Related Costs 3 month | Noncash Merger Related Costs 6 month |
|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $0.00 10-Q · filed 2025-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | |
| 2024-06-30 | -$4.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $42.00K 10-Q · filed 2025-07-30 |
| 2024-03-31 | $4.82M 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |